Chao Yie Yang

What is he best known for?

The fields of study he is best known for:

• Gene
• Enzyme
• Biochemistry

Chao Yie Yang mostly deals with Biochemistry, Apoptosis, Cell biology, XIAP and Cancer research. His study focuses on the intersection of Apoptosis and fields such as Cell culture with connections in the field of Cell growth, Small molecule, Leukemia, STAT3 and Myeloid leukemia. His research integrates issues of Caspase, Activator and DNA-binding protein in his study of Cell biology.

As part of the same scientific family, Chao Yie Yang usually focuses on XIAP, concentrating on Inhibitor of apoptosis and intersecting with Pharmacology, Orally active, Bioavailability, Antagonist and Cancer cell. His Cancer research research is multidisciplinary, incorporating elements of Clinical trial, Mdm2, Mdm2 p53, Function and STAT protein. His research in Structure–activity relationship intersects with topics in Combinatorial chemistry, Smac mimetics, Protein structure and Stereochemistry.

His most cited work include:

• The PDBbind database: methodologies and updates. (407 citations)
• Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. (246 citations)
• A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment (185 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of study are Cancer research, Small molecule, Biochemistry, Cell growth and Apoptosis. His work carried out in the field of Cancer research brings together such families of science as Proteolysis targeting chimera, Cancer, Molecular biology, Androgen receptor and In vivo. His study in Small molecule is interdisciplinary in nature, drawing from both Ligand binding assay, Biophysics, Stereochemistry, Peptidomimetic and Binding site.

He has included themes like Cell culture, Bromodomain, BRD4, Programmed cell death and Structure–activity relationship in his Cell growth study. His Apoptosis research incorporates elements of Cancer cell, In vitro, Cytotoxicity and Cell biology. His XIAP study integrates concerns from other disciplines, such as Inhibitor of apoptosis, Smac mimetics, Combinatorial chemistry and Bivalent.

He most often published in these fields:

• Cancer research (28.33%)
• Small molecule (26.67%)
• Biochemistry (26.67%)

What were the highlights of his more recent work (between 2018-2021)?

• Cancer research (28.33%)
• Cell growth (24.17%)
• Cancer (10.83%)

In recent papers he was focusing on the following fields of study:

His main research concerns Cancer research, Cell growth, Cancer, Proteolysis targeting chimera and Cell culture. His Cell growth research is multidisciplinary, relying on both Mutation, IC50 and Oral administration, Pharmacology. The study incorporates disciplines such as Receptor, Protein degradation and Proteolysis in addition to Proteolysis targeting chimera.

The research on Cell biology and Biochemistry is part of his Protein degradation project. Chao Yie Yang combines subjects such as EZH2, Myeloid leukemia, Small molecule, Structure–activity relationship and In vivo with his study of Cell culture. The Myeloid leukemia study combines topics in areas such as Cancer cell, Apoptosis, Leukemia and Kinase.

Between 2018 and 2021, his most popular works were:

• A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo (91 citations)
• Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. (88 citations)
• Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression. (81 citations)

In his most recent research, the most cited papers focused on:

• Gene
• Enzyme
• Cancer

His scientific interests lie mostly in Cancer research, Proteolysis targeting chimera, Cell growth, Protein degradation and Proteolysis. His studies in Cancer research integrate themes in fields like Cell culture and STAT3, STAT protein. His research on Cell culture frequently connects to adjacent areas such as In vivo.

To a larger extent, he studies Apoptosis with the aim of understanding STAT3. His Cell growth research integrates issues from Ubiquitin ligase, Receptor and Androgen receptor, LNCaP, Prostate cancer. His Protein degradation study is focused on Biochemistry in general.